Anti-tumour immunity induces aberrant peptide presentation in melanoma.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
02 2021
Historique:
received: 09 01 2020
accepted: 30 10 2020
pubmed: 18 12 2020
medline: 10 3 2021
entrez: 17 12 2020
Statut: ppublish

Résumé

Extensive tumour inflammation, which is reflected by high levels of infiltrating T cells and interferon-γ (IFNγ) signalling, improves the response of patients with melanoma to checkpoint immunotherapy

Identifiants

pubmed: 33328638
doi: 10.1038/s41586-020-03054-1
pii: 10.1038/s41586-020-03054-1
doi:

Substances chimiques

Codon 0
Histocompatibility Antigens Class I 0
IDO1 protein, human 0
Indoleamine-Pyrrole 2,3,-Dioxygenase 0
Peptides 0
Proteome 0
Interferon-gamma 82115-62-6
Tryptophan 8DUH1N11BX

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

332-337

Subventions

Organisme : European Research Council
Pays : International

Commentaires et corrections

Type : CommentIn

Références

Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930–2940 (2017).
pubmed: 28650338 pmcid: 5531419
Ji, R. R. et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61, 1019–1031 (2012).
pubmed: 22146893
Timosenko, E. et al. Nutritional stress induced by tryptophan-degrading enzymes results in ATF4-dependent reprogramming of the amino acid transporter profile in tumor cells. Cancer Res. 76, 6193–6204 (2016).
pubmed: 27651314 pmcid: 5096689
Zhai, L. et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin. Cancer Res. 21, 5427–5433 (2015).
pubmed: 26519060 pmcid: 4681601
Amobi, A., Qian, F., Lugade, A. A. & Odunsi, K. Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression. Adv. Exp. Med. Biol. 1036, 129–144 (2017).
pubmed: 29275469
Labadie, B. W., Bao, R. & Luke, J. J. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin. Cancer Res. 25, 1462–1471 (2019).
pubmed: 30377198
Günther, J., Däbritz, J. & Wirthgen, E. Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment. Front. Immunol. 10, 1801 (2019).
pubmed: 31417567 pmcid: 6682646
Battu, S., Minhas, G., Mishra, A. & Khan, N. Amino acid sensing via general control nonderepressible-2 kinase and immunological programming. Front. Immunol. 8, 1719 (2017).
pubmed: 29321774 pmcid: 5732134
Wek, R. C. & Staschke, K. A. How do tumours adapt to nutrient stress? EMBO J. 29, 1946–1947 (2010).
pubmed: 20551969 pmcid: 2892365
Ye, J. et al. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 29, 2082–2096 (2010).
pubmed: 20473272 pmcid: 2892366
Adam, I. et al. Upregulation of tryptophanyl-tRNA synthethase adapts human cancer cells to nutritional stress caused by tryptophan degradation. OncoImmunology 7, e1486353 (2018).
pubmed: 30524887 pmcid: 6279332
Loayza-Puch, F. et al. Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature 530, 490–494 (2016).
pubmed: 26878238
Bhushan, S. et al. α-Helical nascent polypeptide chains visualized within distinct regions of the ribosomal exit tunnel. Nat. Struct. Mol. Biol. 17, 313–317 (2010).
pubmed: 20139981
Woolhead, C. A., McCormick, P. J. & Johnson, A. E. Nascent membrane and secretory proteins differ in FRET-detected folding far inside the ribosome and in their exposure to ribosomal proteins. Cell 116, 725–736 (2004).
pubmed: 15006354
Caliskan, N. et al. Conditional switch between frameshifting regimes upon translation of dnaX mRNA. Mol. Cell 66, 558–567 (2017).
pubmed: 28525745
Yelverton, E., Lindsley, D., Yamauchi, P. & Gallant, J. A. The function of a ribosomal frameshifting signal from human immunodeficiency virus-1 in Escherichia coli. Mol. Microbiol. 11, 303–313 (1994).
pubmed: 8170392 pmcid: 7192232
Gurvich, O. L., Baranov, P. V., Gesteland, R. F. & Atkins, J. F. Expression levels influence ribosomal frameshifting at the tandem rare arginine codons AGG_AGG and AGA_AGA in Escherichia coli. J. Bacteriol. 187, 4023–4032 (2005).
pubmed: 15937165 pmcid: 1151738
Olubajo, B. & Taylor, E. W. A. A −1 frameshift in the HIV-1 env gene is enhanced by arginine deficiency via a hungry codon mechanism. Mutat. Res. 579, 125–132 (2005).
pubmed: 16055159
Barak, Z., Lindsley, D. & Gallant, J. On the mechanism of leftward frameshifting at several hungry codons. J. Mol. Biol. 256, 676–684 (1996).
pubmed: 8642590
Lainé, S., Thouard, A., Komar, A. A. & Rossignol, J. M. Ribosome can resume the translation in both +1 or −1 frames after encountering an AGA cluster in Escherichia coli. Gene 412, 95–101 (2008).
pubmed: 18313865
Temperley, R., Richter, R., Dennerlein, S., Lightowlers, R. N. & Chrzanowska-Lightowlers, Z. M. Hungry codons promote frameshifting in human mitochondrial ribosomes. Science 327, 301 (2010).
pubmed: 20075246
Vredevoogd, D. W. et al. Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold. Cell 178, 585–599 (2019).
pubmed: 31303383
Zhou, F. Molecular mechanisms of IFN-γ to up-regulate MHC class I antigen processing and presentation. Int. Rev. Immunol. 28, 239–260 (2009).
pubmed: 19811323
Bourdetsky, D., Schmelzer, C. E. & Admon, A. The nature and extent of contributions by defective ribosome products to the HLA peptidome. Proc. Natl Acad. Sci. USA 111, E1591–E1599 (2014).
pubmed: 24715725 pmcid: 4000780
Yewdell, J. W. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol. 32, 548–558 (2011).
pubmed: 21962745 pmcid: 3200450
Trentini, D. B. et al. Role for ribosome-associated quality control in sampling proteins for MHC class I-mediated antigen presentation. Proc. Natl Acad. Sci. USA 117, 4099–4108 (2020).
pubmed: 32047030 pmcid: 7049129
Erhard, F. et al. Improved Ribo-seq enables identification of cryptic translation events. Nat. Methods 15, 363–366 (2018).
pubmed: 29529017 pmcid: 6152898
Prasad, S., Starck, S. R. & Shastri, N. Presentation of cryptic peptides by MHC class I is enhanced by inflammatory stimuli. J. Immunol. 197, 2981–2991 (2016).
pubmed: 27647836
Starck, S. R. & Shastri, N. Nowhere to hide: unconventional translation yields cryptic peptides for immune surveillance. Immunol. Rev. 272, 8–16 (2016).
pubmed: 27319338 pmcid: 4916849
Chen, J. et al. Pervasive functional translation of noncanonical human open reading frames. Science 367, 1140–1146 (2020).
pubmed: 32139545 pmcid: 7289059
Chong, C. et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020).
pubmed: 32157095 pmcid: 7064602
Laumont, C. M. & Perreault, C. Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy. Cell. Mol. Life Sci. 75, 607–621 (2018).
pubmed: 28823056
Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 10, eaau5516 (2018).
pubmed: 30518613
Pearson, H. et al. MHC class I-associated peptides derive from selective regions of the human genome. J. Clin. Invest. 126, 4690–4701 (2016).
pubmed: 27841757 pmcid: 5127664
Laumont, C. M. et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat. Commun. 7, 10238 (2016).
pubmed: 26728094 pmcid: 4728431
Saulquin, X. et al. +1 Frameshifting as a novel mechanism to generate a cryptic cytotoxic T lymphocyte epitope derived from human interleukin 10. J. Exp. Med. 195, 353–358 (2002).
pubmed: 11828010 pmcid: 2193594
Dersh, D., Yewdell, J. W. & Wei, J. A SIINFEKL-based system to measure MHC class I antigen presentation efficiency and kinetics. Methods Mol. Biol. 1988, 109–122 (2019).
pubmed: 31147936 pmcid: 6661116
McCarthy, M. K. & Weinberg, J. B. The immunoproteasome and viral infection: a complex regulator of inflammation. Front. Microbiol. 6, 21 (2015).
pubmed: 25688236 pmcid: 4310299
Goldberg, A. L., Cascio, P., Saric, T. & Rock, K. L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol. Immunol. 39, 147–164 (2002).
pubmed: 12200047
Kalaora, S. et al. Combined analysis of antigen presentation and t-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 8, 1366–1375 (2018).
pubmed: 30209080 pmcid: 6453138
Strønen, E. et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337–1341 (2016).
pubmed: 27198675
Ali, M. et al. Induction of neoantigen-reactive T cells from healthy donors. Nat. Protocols 14, 1926–1943 (2019).
pubmed: 31101906
Dong, L., Li, P., Oenema, T., McClurkan, C. L. & Koelle, D. M. Public TCR use by herpes simplex virus-2-specific human CD8 CTLs. J. Immunol. 184, 3063–3071 (2010).
pubmed: 20139278
Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10–12 (2011).
Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766–D773 (2019).
pubmed: 30357393
Langmead, B. Aligning short sequencing reads with Bowtie. Curr. Protoc. Bioinformatics 32, 11.7.1–11.7.14 (2010).
Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
pubmed: 23618408 pmcid: 4053844
Lauria, F. et al. riboWaltz: optimization of ribosome P-site positioning in ribosome profiling data. PLoS Comput. Biol. 14, e1006169 (2018).
pubmed: 30102689 pmcid: 6112680
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700
Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
pubmed: 20979621 pmcid: 3218662
Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841–842 (2010).
pubmed: 20110278 pmcid: 2832824
Rainer, J., Gatto, L. & Weichenberger, C. X. ensembldb: an R package to create and use Ensembl-based annotation resources. Bioinformatics 35, 3151–3153 (2019).
pubmed: 30689724 pmcid: 6736197
Jersie-Christensen, R. R., Sultan, A. & Olsen, J. V. Simple and reproducible sample preparation for single-shot phosphoproteomics with high sensitivity. Methods Mol. Biol. 1355, 251–260 (2016).
pubmed: 26584931
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).
pubmed: 27348712
Ameziane, N. et al. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. Nat. Commun. 6, 8829 (2015).
pubmed: 26681308
Zerbino, D. R. et al. Ensembl 2018. Nucleic Acids Res. 46, D754–D761 (2018).
pubmed: 29155950
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
pubmed: 19029910
UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506–D515 (2019).
Zhang, X. et al. Proteome-wide identification of ubiquitin interactions using UbIA-MS. Nat. Protocols 13, 530–550 (2018).
pubmed: 29446774
Kalaora, S. et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 7, 5110–5117 (2016).
pubmed: 26819371 pmcid: 4868674
Fu, L., Niu, B., Zhu, Z., Wu, S. & Li, W. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics 28, 3150–3152 (2012).
pubmed: 23060610 pmcid: 3516142
Jurtz, V. et al. NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360–3368 (2017).
pubmed: 28978689
Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinformatics 43, 11.10.1–11.10.33 (2013).
Li, H. D., Funk, C. C. & Price, N. D. iREAD: a tool for intron retention detection from RNA-seq data. BMC Genomics 21, 128 (2020).
pubmed: 32028886 pmcid: 7006120
Andreatta, M., Alvarez, B. & Nielsen, M. GibbsCluster: unsupervised clustering and alignment of peptide sequences. Nucleic Acids Res. 45, W458–W463 (2017).
pubmed: 28407089 pmcid: 5570237
Vita, R. et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 47, D339–D343 (2019).
pubmed: 30357391
Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315–326 (2017).
pubmed: 28228285 pmcid: 5405381
Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199–209 (2020).
pubmed: 31844290
Krokhin, O. V. & Spicer, V. Peptide retention standards and hydrophobicity indexes in reversed-phase high-performance liquid chromatography of peptides. Anal. Chem. 81, 9522–9530 (2009).
pubmed: 19848410
Gatto, L. & Lilley, K. S. MSnbase-an R/Bioconductor package for isobaric tagged mass spectrometry data visualization, processing and quantitation. Bioinformatics 28, 288–289 (2012).
pubmed: 22113085
MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 26, 966–968 (2010).
pubmed: 20147306 pmcid: 2844992
Mészáros, B., Erdos, G. & Dosztányi, Z. IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding. Nucleic Acids Res. 46, W329–W337 (2018).
pubmed: 29860432 pmcid: 6030935
Ingolia, N. T., Brar, G. A., Rouskin, S., McGeachy, A. M. & Weissman, J. S. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments. Nat. Protocols 7, 1534–1550 (2012).
pubmed: 22836135
Toebes, M. et al. Design and use of conditional MHC class I ligands. Nat. Med. 12, 246–251 (2006).
pubmed: 16462803
Hadrup, S. R. et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520–526 (2009).
pubmed: 19543285
Philips, D., van den Braber, M., Schumacher, T. N. & Kvistborg, P. pMHC multiplexing strategy to detect high numbers of T cell responses in parallel. Methods Mol. Biol. 1514, 93–101 (2017).
pubmed: 27787794
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
pubmed: 30395289

Auteurs

Osnat Bartok (O)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

Abhijeet Pataskar (A)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Remco Nagel (R)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Maarja Laos (M)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Eden Goldfarb (E)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

Deborah Hayoun (D)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

Ronen Levy (R)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

Pierre-Rene Körner (PR)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Inger Z M Kreuger (IZM)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Julien Champagne (J)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Esther A Zaal (EA)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.
Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Onno B Bleijerveld (OB)

Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Xinyao Huang (X)

Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Juliana Kenski (J)

Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Jennifer Wargo (J)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Alexander Brandis (A)

Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.

Yishai Levin (Y)

The Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.

Orel Mizrahi (O)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.

Michal Alon (M)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

Sacha Lebon (S)

Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.

Weiwen Yang (W)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Morten M Nielsen (MM)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Noam Stern-Ginossar (N)

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.

Maarten Altelaar (M)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.
Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Celia R Berkers (CR)

Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.
Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Tamar Geiger (T)

Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Daniel S Peeper (DS)

Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Johanna Olweus (J)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Yardena Samuels (Y)

Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Yardena.Samuels@weizmann.ac.il.

Reuven Agami (R)

Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.agami@nki.nl.
Erasmus MC, Rotterdam University, Rotterdam, The Netherlands. r.agami@nki.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH